Form 8-K · Current Report · Filed 2024-04-29
Revvity Reports Q1 2024 Financial Results and Reaffirms Guidance
Revvity, Inc. reported its financial results for the first quarter of 2024 on April 29, 2024. The company announced GAAP earnings per share (EPS) of $0.21, compared to $4.50 in the same period of the previous year. GAAP revenue was $650 million, showing a 4% decrease from the previous year's $675 million. Adjusted EPS from continuing operations was $0.98, down from $1.01 in the first quarter of 2023. The company reaffirmed its full-year 2024 guidance for organic growth and adjusted EPS.
- Filer
- Revvity Inc. RVTY · NYSE
- Filed
- Accession
- 0001628280-24-018795
- CIK
- 0000031791
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Financial Statements and Exhibits
Market reaction
Close before filing
$101.51
Next session
+0.9%
Since filing
+44.5%
Latest close
$146.73
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from RVTY reporting the same item, with the next session's move:
Exhibits (1)
About Revvity Inc.
Revvity Inc. is a prominent company in the healthcare and biological sciences field, offering a comprehensive suite of solutions aimed at improving global health outcomes. The company's core focus lies in delivering innovative products and services that range from diagnostic tools to advanced analytical capabilities for life sciences research. Revvity serves a wide array of sectors including biotechnology, pharmaceuticals, and clinical diagnostics, providing essential tools and data analytics that aid in disease discovery, drug development, and health monitoring. The company's expertise in deploying cutting-edge technologies further reinforces its position as a critical enabler of scientific research and innovation. With its global reach and commitment to enhancing healthcare delivery, Revvity Inc. plays a pivotal role in advancing the capabilities of medical and scientific communities worldwide, driving progress in critical areas such as personalized medicine and preventive healthcare.
Never miss another RVTY filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.